The U.S. Food and Drug Administration (FDA) has issued an updated guidance document, “Intent to Exempt Certain Unclassified Medical Devices from Premarket Notification Requirements”, on June 5, 2026.
This guidance supersedes the previous version issued on June 14, 2019, and reflects the FDA’s current approach regarding exemptions from premarket notification (510(k)) requirements for certain unclassified medical devices.
The document provides the FDA’s nonbinding recommendations and explains the Agency’s intent to exempt specific unclassified devices from premarket notification requirements where such requirements are no longer considered necessary to provide reasonable assurance of safety and effectiveness.
Manufacturers of unclassified medical devices should review the updated guidance carefully to determine whether their products may qualify for exemption and to understand any applicable limitations or conditions associated with such exemptions.
The update is part of the FDA’s ongoing efforts to modernize regulatory oversight, reduce unnecessary regulatory burden, and allocate resources more efficiently while continuing to protect public health.
The full FDA guidance document i can be accessed here.
If you have questions regarding the potential impact of this guidance on your medical devices, the MDSS regulatory team is available to assist with regulatory assessment and compliance support for the U.S. market.
